158 related articles for article (PubMed ID: 17081164)
1. An open-label study of rabeprazole in patients with Zollinger-Ellison syndrome or idiopathic gastric acid hypersecretion.
Morocutti A; Merrouche M; Bjaaland T; Humphries T; Mignon M
Aliment Pharmacol Ther; 2006 Nov; 24(10):1439-44. PubMed ID: 17081164
[TBL] [Abstract][Full Text] [Related]
2. Maintenance oral pantoprazole therapy is effective for patients with Zollinger-Ellison syndrome and idiopathic hypersecretion.
Metz DC; Soffer E; Forsmark CE; Cryer B; Chey W; Bochenek W; Pisegna JR
Am J Gastroenterol; 2003 Feb; 98(2):301-7. PubMed ID: 12591045
[TBL] [Abstract][Full Text] [Related]
3. Replacement of oral proton pump inhibitors with intravenous pantoprazole to effectively control gastric acid hypersecretion in patients with Zollinger-Ellison syndrome.
Metz DC; Forsmark C; Lew EA; Starr JA; Soffer EF; Bochenek W; Pisegna JR
Am J Gastroenterol; 2001 Dec; 96(12):3274-80. PubMed ID: 11774936
[TBL] [Abstract][Full Text] [Related]
4. Treatment of patients with Zollinger-Ellison syndrome.
Mignon M; Pospai D; Forestier S; Vatier J; Vallot T
Clin Ther; 1993; 15 Suppl B():22-31. PubMed ID: 8205592
[TBL] [Abstract][Full Text] [Related]
5. Long-term treatment with lansoprazole of patients with duodenal ulcer and basal acid output of more than 15 mmol/h.
Hirschowitz BI; Mohnen J; Shaw S
Aliment Pharmacol Ther; 1996 Aug; 10(4):497-506. PubMed ID: 8853753
[TBL] [Abstract][Full Text] [Related]
6. Long-term lansoprazole control of gastric acid and pepsin secretion in ZE and non-ZE hypersecretors: a prospective 10-year study.
Hirschowitz BI; Simmons J; Mohnen J
Aliment Pharmacol Ther; 2001 Nov; 15(11):1795-806. PubMed ID: 11683694
[TBL] [Abstract][Full Text] [Related]
7. Effects of esomeprazole on acid output in patients with Zollinger-Ellison syndrome or idiopathic gastric acid hypersecretion.
Metz DC; Sostek MB; Ruszniewski P; Forsmark CE; Monyak J; Pisegna JR
Am J Gastroenterol; 2007 Dec; 102(12):2648-54. PubMed ID: 17764495
[TBL] [Abstract][Full Text] [Related]
8. Helicobacter pylori effects on gastritis, gastrin and enterochromaffin-like cells in Zollinger-Ellison syndrome and non-Zollinger-Ellison syndrome acid hypersecretors treated long-term with lansoprazole.
Hirschowitz BI; Haber MM
Aliment Pharmacol Ther; 2001 Jan; 15(1):87-103. PubMed ID: 11136282
[TBL] [Abstract][Full Text] [Related]
9. Presentation, response to lansoprazole therapy, and outcome of Zollinger-Ellison syndrome-like gastric acid hypersecretors.
Wilcox CM; Seay T; Arcury J; Hirschowitz BI
Scand J Gastroenterol; 2011 Mar; 46(3):277-80. PubMed ID: 21073392
[TBL] [Abstract][Full Text] [Related]
10. A prospective study of the effectiveness of low dose omeprazole as initial therapy in Zollinger-Ellison syndrome.
Termanini B; Gibril F; Stewart CA; Weber HC; Jensen RT
Aliment Pharmacol Ther; 1996 Feb; 10(1):61-71. PubMed ID: 8871445
[TBL] [Abstract][Full Text] [Related]
11. Long-term treatment with lansoprazole for patients with Zollinger-Ellison syndrome.
Hirschowitz BI; Mohnen J; Shaw S
Aliment Pharmacol Ther; 1996 Aug; 10(4):507-22. PubMed ID: 8853754
[TBL] [Abstract][Full Text] [Related]
12. Zollinger-Ellison syndrome: presentation, response to therapy, and outcome.
Wilcox CM; Seay T; Arcury JT; Mohnen J; Hirschowitz BI
Dig Liver Dis; 2011 Jun; 43(6):439-43. PubMed ID: 21193359
[TBL] [Abstract][Full Text] [Related]
13. Prospective study of efficacy and safety of lansoprazole in Zollinger-Ellison syndrome.
Metz DC; Pisegna JR; Ringham GL; Feigenbaum K; Koviack PD; Maton PN; Gardner JD; Jensen RT
Dig Dis Sci; 1993 Feb; 38(2):245-56. PubMed ID: 8425437
[TBL] [Abstract][Full Text] [Related]
14. [Dose-response effect of lansoprazole in patients with Zollinger-Ellison syndrome].
Mignon M; Hochlaf S; Forestier S; Ruszniewski P; Vatier J; Joubert-Collin M
Gastroenterol Clin Biol; 1994; 18(1):13-6. PubMed ID: 8187984
[TBL] [Abstract][Full Text] [Related]
15. Reliability of symptoms in assessing control of gastric acid secretion in patients with Zollinger-Ellison syndrome.
Raufman JP; Collins SM; Pandol SJ; Korman LY; Collen MJ; Cornelius MJ; Feld MK; McCarthy DM; Gardner JD; Jensen RT
Gastroenterology; 1983 Jan; 84(1):108-13. PubMed ID: 6128284
[TBL] [Abstract][Full Text] [Related]
16. Three-year oral pantoprazole administration is effective for patients with Zollinger-Ellison syndrome and other hypersecretory conditions.
Metz DC; Comer GM; Soffer E; Forsmark CE; Cryer B; Chey W; Pisegna JR
Aliment Pharmacol Ther; 2006 Feb; 23(3):437-44. PubMed ID: 16423003
[TBL] [Abstract][Full Text] [Related]
17. Role of acid suppressants in patients with Zollinger-Ellison syndrome.
Maton PN
Aliment Pharmacol Ther; 1991; 5 Suppl 1():25-35. PubMed ID: 1679671
[TBL] [Abstract][Full Text] [Related]
18. Intravenous pantoprazole rapidly controls gastric acid hypersecretion in patients with Zollinger-Ellison syndrome.
Lew EA; Pisegna JR; Starr JA; Soffer EF; Forsmark C; Modlin IM; Walsh JH; Beg M; Bochenek W; Metz DC
Gastroenterology; 2000 Apr; 118(4):696-704. PubMed ID: 10734021
[TBL] [Abstract][Full Text] [Related]
19. Chromogranin A in patients with acid hypersecretion and/or hypergastrinaemia.
Hirschowitz BI; Worthington J; Mohnen J; Haber M
Aliment Pharmacol Ther; 2007 Sep; 26(6):869-78. PubMed ID: 17767471
[TBL] [Abstract][Full Text] [Related]
20. Use of omeprazole in Zollinger-Ellison syndrome: a prospective nine-year study of efficacy and safety.
Metz DC; Strader DB; Orbuch M; Koviack PD; Feigenbaum KM; Jensen RT
Aliment Pharmacol Ther; 1993 Dec; 7(6):597-610. PubMed ID: 8161665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
